December 1, 2020 -- ViGeneron and WuXi Advanced Therapies have announced the formation of a strategic partnership to accelerate the clinical development of VG901, a next-generation ophthalmic gene therapy program.
ViGeneron's VG901 targets a disease gene for retinitis pigmentosa (RP), for which there are currently no approved treatment options. VG901 was developed using ViGeneron's proprietary vg adeno-associated virus (vgAAV) vector platform that allows superior transduction of retinal cells intravitreally, which is a less invasive treatment method.
As a contract testing, development, and manufacturing organization, WuXi will accelerate the development of VG901 by manufacturing, testing, and making available the clinical trial product, leveraging its AAV suspension and plasmid DNA platforms.
The companies plan to begin manufacturing by the end of 2020.
Copyright © 2020 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
